AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 DEC 5 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in Japan have isolated a novel antibody that can protect cells from HIV infection via the CCR5 coreceptor.
Shogo Misumi and colleagues at Kumamoto University in Kumamoto described the development of this monoclonal antibody in the December 2001 edition of the Journal of Virology.
The antibody - dubbed KB8C12 or immunoglobulin M (kappa) - may represent a potential vaccine against CCR5-tropic strains of HIV, the researchers said.
Misumi and coworkers first developed a cyclic closed-chain dodecapeptide, cDDR5, which emulated CCR5's conformation-specific domain. Immunoglobulin M (kappa) is a purified monoclonal antibody to cDDR5 conjugated with a multiple-antigen peptide (cDDR5-MAP), according to their report.
This antibody strongly inhibited the activity of macrophage inflammatory protein (MIP)-1 (beta), which is thought to play a role in CCR5-tropic HIV cell entry. At low nanomolar concentrations (as low as 1.67 nM), immunoglobulin M (kappa) afforded cells near-total protection against R5 HIV infection, study data showed.
In addition, cDDR5-MAP alone was also able to block HIV cell entry through CCR5 although only at high micromolar ...
Source: HighBeam Research, Novel Antibody Potently Inhibits R5 HIV Strains.(Brief Article)